YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy.

Lam, Wing; Arammash, Mohammad; Cai, Wei; Guan, Fulan; Jiang, Zaoli; Liu, Shwu-Huey; Cheng, Peikwen; Cheng, Yung-Chi

Lam, Wing; Arammash, Mohammad; Cai, Wei; Guan, Fulan; Jiang, Zaoli; Liu, Shwu-Huey; Cheng, Peikwen; Cheng, Yung-Chi.

Afiliación

Lam W; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, United States.
Arammash M; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, United States.
Cai W; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, United States.
Guan F; School of Pharmaceutical Sciences, Hunan University of Medicine, Huaihua, China.
Jiang Z; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, United States.
Liu SH; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, United States.
Cheng P; Yiviva, Inc, New York, NY, United States.
Cheng YC; Yiviva, Inc, New York, NY, United States.

Front Pharmacol ; 14: 1244655, 2023.

Article en En | MEDLINE | ID: mdl-37860121

Palabras clave

AR; GR; YIV-818-A; and enzalutamide; apalutamide; darolutamide; prostate cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos